Perspectives
Review Articles
Podcasts
Video Center
CLL News Archive
Ask Our Advisors
Register for Updates
Be notified when new content and features are added to CLLPerspectives.com. Go

The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia
Source: Leukemia Hematology - June 14, 2007

The management of chronic lymphocytic leukemia (CLL) has historically relied on 'watchful waiting' and palliative approaches to therapy. However, the course of disease is highly variable and a substantial proportion of patients with early-stage CLL develop rapidly progressive disease requiring therapy. In recent decades, numerous clinical and biological prognostic markers that are predictive of decreased survival outcomes, disease progression and/or resistance to therapy, and that may play a role in defining the subgroups of patients with 'high-risk' CLL have been identified. At the same time, highly effective treatment modalities have become available with the advent of chemoimmunotherapy combinations and allogeneic stem cell transplantation. Thus, we are approaching an era when patients with CLL may potentially benefit from individualized risk assessments based on prognostic markers and when specific therapies may be offered to the subgroup of patients with high-risk disease. This review provides a brief overview of newer biological prognostic markers, discusses the challenges associated with identifying the subgroup of patients with high-risk CLL and further aims to provide recommendations on how prognostic markers may be used to assess high-risk subgroups in different clinical situations in CLL.

Click on the links below to view news articles on Chronic Lymphocytic Leukemia from the past six months.

CLL News & Commentary - provided by Medworm

Rituximab confirmed as cost effective for CLL in Romania Source: PharmacoEconomics and Outcomes News - Sunday, July 25, 2010
Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression Source: Modern Pathology AOP - Thursday, July 22, 2010
Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms Source: British Journal of Haematology - Wednesday, July 21, 2010
Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients Source: British Journal of Cancer AOP - Monday, July 19, 2010
Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies [REVIEW ARTICLES] Source: Journal of Clinical Oncology - Friday, July 16, 2010
Telomere dysfunction-induced foci arise with the onset of telomeric deletions and complex chromosomal aberrations in resistant chronic lymphocytic leukemia cells Source: Blood - Thursday, July 15, 2010
Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case Source: Cancer Genetics and Cytogenetics - Thursday, July 15, 2010
Lycorine sensitizes CD40L protected chronic lymphocytic leukemia cells to bezafibrate and medroxyprogesterone acetate induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance. Source: Haematologica - Wednesday, July 14, 2010
Allogeneic Stem Cell Transplantation Successfully Treats Therapy-Resistant Chronic Leukemia Source: Health News from Medical News Today - Wednesday, July 14, 2010
Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome Source: Annals of Hematology - Tuesday, July 13, 2010
Stem cell transplantation successfully treats therapy-resistant chronic leukemia, German study finds Source: ScienceDaily Headlines - Tuesday, July 13, 2010
Stem cell transplantation of therapy-resistant chronic leukemia successful Source: EurekAlert! - Medicine and Health - Monday, July 12, 2010
Rituximab: A Review of its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Source: Drugs - Saturday, July 10, 2010
A Rare Case of Chronic Lymphocytic Leukemia with Hypercalcemia Induced by Elevated Parathyroid Hormone-Related Peptides Source: Karger Publishers - Thursday, July 08, 2010
A Rare Case of Chronic Lymphocytic Leukemia with Hypercalcemia Induced by Elevated Parathyroid Hormone-Related Peptides. Source: Acta Haematologica - Thursday, July 08, 2010
Arsenic Trioxide and the PI3K/AKT Pathway in Chronic Lymphocytic Leukemia. Source: Clinical Cancer Research - Thursday, July 08, 2010
17-DMAG targets the nuclear factor-{kappa}B family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition Source: Blood - Thursday, July 08, 2010
LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells Source: Leukemia - Wednesday, July 07, 2010
Patients with treatment-resistant CLL respond positively to stem cell transplants Source: ScienceDaily Headlines - Wednesday, July 07, 2010
Mantle cell lymphoma and chronic lymphocytic leukemia: report of a rare disease association and review of the literature Source: Journal of Hematopathology - Tuesday, July 06, 2010
Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression [Medical_Sciences] Source: Proceedings of the National Academy of Sciences - Tuesday, July 06, 2010
Bendamustine for the Treatment of Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Source: Medscape Today Headlines - Tuesday, July 06, 2010
Bendamustine for the Treatment of Indolent Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Source: Medscape Today Headlines - Tuesday, July 06, 2010
Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells Source: Oncogene - Sunday, July 04, 2010
Patients With Treatment-Resistant Chronic Leukemia Respond Positively to Stem Cell Transplants Source: Drugs.com - Clinical Trials - Friday, July 02, 2010
Patients With Treatment-Resistant Chronic Leukemia Respond Positively To Stem Cell Transplants Source: Health News from Medical News Today - Friday, July 02, 2010
ROR1 expression is not a unique marker of CLL Source: Hematological Oncology - Thursday, July 01, 2010
U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab. Source: Clinical Cancer Research - Thursday, July 01, 2010
Diminished Sensitivity of Chronic Lymphocytic Leukemia cells to ABT-737 and ABT-263 Due to Albumin Binding in Blood. Source: Clinical Cancer Research - Thursday, July 01, 2010
Minocycline is cytoprotective in human corneal endothelial cells and induces anti-apoptotic B-cell CLL/lymphoma 2 (Bcl-2) and X-linked inhibitor of apoptosis (XIAP) Source: British Journal of Ophthalmology - Thursday, July 01, 2010
Patients with treatment-resistant CLL respond positively to stem cell transplants Source: EurekAlert! - Medicine and Health - Thursday, July 01, 2010
Abstract #11: The Disruptions to Cognition, Everyday Function, and Quality of Life in Oncology Patients: A Therapeutic Opportunity? Source: Neurotherapeutics - Wednesday, June 30, 2010
A patient with CLL and a dry cough Source: BMJ Online First - Wednesday, June 30, 2010
Neuer Therapieansatz bei refraktärer CLL Arzerra® (Ofatumumab): Neuartiger CD20-Antikörper jetzt zugelassen Source: Karger Publishers - Tuesday, June 29, 2010
Dichotomy in NF-κB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering Source: Oncogene - Sunday, June 27, 2010
Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis Source: Environmental Health - Sunday, June 27, 2010
The autocrine motility factor receptor is overexpressed on the surface of B cells in Binet C chronic lymphocytic leukemia Source: Medical Oncology - Friday, June 25, 2010
Possible prognostic value of nucleolar morphology in pathologic cells of B-chronic lymphocytic leukemia. Source: Neoplasma - Friday, June 25, 2010
Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia Source: Cancer - Thursday, June 24, 2010
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways Source: Blood - Thursday, June 24, 2010
NICE issues Appraisal Consultation Document on ofatumumab for chronic lymphocytic leukaemia Source: NeLM - News - Wednesday, June 23, 2010
Chronic lymphocytic leukemia breakthrough: green tea extract halts cancer progression in majority of patients Source: NaturalNews.com - Wednesday, June 23, 2010
Semafore Pharmaceuticals Presents New Clinical Data On Novel Prodrug Dual PI3K-mTOR Inhibitor In B-Cell Malignancies And Solid Tumors Source: Health News from Medical News Today - Wednesday, June 23, 2010
Semafore Pharmaceuticals Presents New Clinical Data on Novel Prodrug Dual PI3K-mTOR Inhibitor in B-Cell Malignancies and Solid Tumors Source: Kidney Cancer Association - Tuesday, June 22, 2010
Ofatumumab turns in encouraging results in pretreated CLL Source: Cancer Network - Tuesday, June 22, 2010
Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia Source: Cancer Genetics and Cytogenetics - Tuesday, June 22, 2010
Deletion of 5q as a rare abnormality in chronic lymphocytic leukemia Source: Cancer Genetics and Cytogenetics - Tuesday, June 22, 2010
The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Potently Induce Apoptosis in Chronic Lymphocytic Leukemia Cells In vitro and In vivo. Source: Cell Research - Monday, June 21, 2010
Semafore Pharmaceuticals Presents New Clinical Data on Novel Prodrug Dual PI3K-mTOR Inhibitor in B-Cell Malignancies and Solid Tumors Source: Drugs.com - Clinical Trials - Monday, June 21, 2010
Clinical Trials Testing For Second Ohio State Cancer Drug Source: Health News from Medical News Today - Monday, June 21, 2010
Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience Source: Hematological Oncology - Sunday, June 20, 2010
CD5-positive chronic B-cell lymphoproliferative disorders: Diagnosis and prognosis of a heterogeneous disease entity Source: Cytometry Part B: Clinical Cytometry - Sunday, June 20, 2010
High Response Rates With Ofatumumab-Based Chemotherapy for CLL Source: Medscape Today Headlines - Friday, June 18, 2010
Second Ohio State cancer drug begins clinical trials testing Source: EurekAlert! - Medicine and Health - Friday, June 18, 2010
Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma [Hematologic Malignancies] Source: Journal of Clinical Oncology - Thursday, June 17, 2010
Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells Source: Blood - Thursday, June 17, 2010
2,3,7,8-Tetrachlorodibenzo-p-dioxin-Mediated Suppression of Toll-Like Receptor Stimulated B-Lymphocyte Activation and Initiation of Plasmacytic Differentiation Source: Toxicological Sciences - Thursday, June 17, 2010
Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters Source: Genes, Chromosomes and Cancer - Tuesday, June 15, 2010
BCR-Mediated Decrease of CXCR4 and CD62L in CLL - Letter Source: Cancer Research - Tuesday, June 15, 2010
BCR-Mediated Decrease of CXCR4 and CD62L in CLL - Response Source: Cancer Research - Tuesday, June 15, 2010
Evidence for a common genetic aetiology in high-risk families with multiple haematological malignancy subtypes Source: British Journal of Haematology - Monday, June 14, 2010
Calistoga Pharmaceuticals Presents Preclinical and Clinical Data Supporting Benefit of First in Class, Novel Mechanism of CAL-101, an Oral Delta Isoform-Selective PI3 Kinase Inhibitor Source: Drugs.com - Clinical Trials - Monday, June 14, 2010
Alemtuzumab: a costly alternative in CLL? Source: PharmacoEconomics and Outcomes News - Sunday, June 13, 2010
Allogeneic transplant outcomes are not affected by body mass index (BMI) in patients with haematological malignancies Source: Annals of Hematology - Thursday, June 10, 2010
Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors Source: Annals of Hematology - Thursday, June 10, 2010
Lack of evidence for direct involvement of Merkel cell polyomavirus (MCV) in chronic lymphocytic leukemia (CLL) Source: Blood - Thursday, June 10, 2010
In vivo targeting of B-cell lymphoma with glycan ligands of CD22 Source: Blood - Thursday, June 10, 2010
Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience Source: Leukemia Research - Thursday, June 10, 2010
Chronic lymphocytic leukemia/small lymphocytic lymphoma with focal D-type cyclin expression in proliferation centers: A report of four cases Source: Leukemia Research - Thursday, June 10, 2010
SLC6A4 expression and anti-proliferative responses to serotonin transporter ligands chlomipramine and fluoxetine in primary B-cell malignancies Source: Leukemia Research - Thursday, June 10, 2010
Erufosine, a novel alkylphosphocholine, induces apoptosis in CLL through a caspase-dependent pathway Source: Leukemia Research - Thursday, June 10, 2010
Green Tea Compound May Fight Leukemia Source: WebMD Health - Thursday, June 10, 2010
Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk Source: British Journal of Haematology - Wednesday, June 09, 2010
BCL3 translocation in CLL with typical phenotype: assessment of frequency, association with cytogenetic subgroups, and prognostic significance Source: British Journal of Haematology - Wednesday, June 09, 2010
The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis Source: Hematological Oncology - Wednesday, June 09, 2010
Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the PI3K/Akt Pathway via JNK Activation and PTEN Upregulation. Source: Clinical Cancer Research - Tuesday, June 08, 2010
Green Tea Compound Slowed Chronic Lymphocytic Leukemia Source: MedicineNet Cancer General - Tuesday, June 08, 2010
Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia Source: British Journal of Haematology - Monday, June 07, 2010
Green Tea Compound Slowed Chronic Lymphocytic Leukemia Source: The Doctors Lounge - Health News - Monday, June 07, 2010
Mutation analysis of the TNFAIP3 (A20) tumor suppressor gene in CLL Source: International Journal of Cancer - Sunday, June 06, 2010
Green Tea Extract Appears To Keep Cancer In Check In Majority Of CLL Patients Source: Health News from Medical News Today - Saturday, June 05, 2010
Green Tea Extract Appears to Keep Cancer in Check in Majority of CLL Patients Source: Mayo Clinic Research News - Friday, June 04, 2010
Green Tea Extract Appears to Keep Cancer in Check in Majority of CLL Patients Source: Mayo Clinic Rochester News - Friday, June 04, 2010
Green Tea Extract Appears to Keep Cancer in Check in Majority of CLL Patients Source: News from Mayo Clinic - Friday, June 04, 2010
Dequalinium induces apoptosis in peripheral blood mononuclear cells isolated from human chronic lymphocytic leukemia Source: Investigational New Drugs - Friday, June 04, 2010
Vascular endothelial growth factor stimulates protein kinase C{beta}II expression in chronic lymphocytic leukemia cells Source: Blood - Thursday, June 03, 2010
High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease Source: Blood - Thursday, June 03, 2010
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia Source: Blood - Thursday, June 03, 2010
Merkel Cell Carcinoma: Incidence, Mortality, and Risk of Other Cancers Source: JNCI - Tuesday, June 01, 2010
CytRx Initiates Phase 2 Clinical Trial With Bafetinib In B-cell Chronic Lymphocytic Leukemia Source: Health News from Medical News Today - Tuesday, June 01, 2010
Erratum: Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence Source: Cancer - Monday, May 31, 2010
Early Low-grade Gastric MALToma Rarely Transforms Into Diffuse Large Cell Lymphoma or Progresses Beyond the Stomach and Regional Lymph Nodes. Source: J Formos Med Assoc - Monday, May 31, 2010
An unbalanced t(15;18)(q21-q22;p11) as the sole cytogenetic aberration in a patient with B-cell chronic lymphocytic leukemia Source: Cancer Genetics and Cytogenetics - Monday, May 31, 2010
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Source: Haematologica - Friday, May 28, 2010
Prognostic factors identify 3 risk groups in the LRF CLL4 trial, independent of treatment allocation. Source: Haematologica - Friday, May 28, 2010
Time to test CLL p53 function Source: Blood - Thursday, May 27, 2010
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia Source: Blood - Thursday, May 27, 2010
Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo Source: Blood - Thursday, May 27, 2010
Variation at the TERT locus and predisposition for cancer Source: Expert Reviews in Molecular Medicine - Thursday, May 27, 2010
The rate of MEFV gene mutations in hematolymphoid neoplasms Source: International Journal of Immunogenetics - Wednesday, May 26, 2010
Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia Source: American Journal of Hematology - Tuesday, May 25, 2010
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia Source: Molecular Cancer - Tuesday, May 25, 2010
SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL) Source: British Journal of Haematology - Tuesday, May 25, 2010
Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells. Source: Arzneimittel-Forschung - Monday, May 24, 2010
Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells Source: Annals of Hematology - Monday, May 24, 2010
Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. Source: International Journal of Clinical and Experimental Pathology - Saturday, May 22, 2010
MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis Source: Medical Oncology - Saturday, May 22, 2010
Guillain–Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: A case report and review of the literature Source: Leukemia Research - Friday, May 21, 2010
Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro Source: Leukemia Research - Friday, May 21, 2010
Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemia Source: Leukemia Research - Friday, May 21, 2010
Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next? Source: Leukemia Research - Friday, May 21, 2010
The role of Bcl-2 family proteins in chronic lymphocytic leukaemia Source: Leukemia Research - Friday, May 21, 2010
Drug in new class of targeted therapies shows early promise against blood-related cancers Source: ScienceDaily Headlines - Thursday, May 20, 2010
Drug In New Class Of Targeted Therapies Shows Early Promise Against Blood-Related Cancers Source: Health News from Medical News Today - Thursday, May 20, 2010
Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia Source: Molecular Cancer - Wednesday, May 19, 2010
Drug In New Class Of Targeted Therapies Shows Early Promise Against Blood-Related Cancers Source: Pharmaceutical Online News - Wednesday, May 19, 2010
Drug in new class of targeted therapies shows early promise against blood-related cancers Source: EurekAlert! - Medicine and Health - Wednesday, May 19, 2010
Variation at the TERT locus and predisposition for cancer Source: Expert Reviews in Molecular Medicine - Tuesday, May 18, 2010
Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study Source: Health and Quality of Life Outcomes - Monday, May 17, 2010
Case report Specific skin manifestation of B-cell chronic lymphocytic leukaemia Source: Articles of Advances in Dermatology and Allergology - TERMEDIA publishing house - Monday, May 17, 2010
Ofatumumab (Arzerra®) now available in the UK for treatment of CLL Source: NeLM - News - Sunday, May 16, 2010
Intrathecal liposomal cytarabine for treatment of leptomeningeal involvement in transformed (Richter's syndrome) and non-transformed B-cell chronic lymphocytic leukaemia in Spain: a report of seven cases Source: British Journal of Haematology - Friday, May 14, 2010
MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia Source: European Journal of Haematology - Thursday, May 13, 2010
MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27 Source: Blood - Thursday, May 13, 2010
Antigens in CLL: themes and variations Source: Blood - Thursday, May 13, 2010
Coding and noncoding: the CLL mix Source: Blood - Thursday, May 13, 2010
Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin Source: Blood - Thursday, May 13, 2010
13q14 deletions in CLL involve cooperating tumor suppressors Source: Blood - Thursday, May 13, 2010
Immune recovery after fludarabine–cyclophosphamide–rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy Source: Leukemia - Wednesday, May 12, 2010
Intraclonal diversification of immunoglobulin light chains in a subset of chronic lymphocytic leukemia alludes to antigen-driven clonal evolution Source: Leukemia - Wednesday, May 12, 2010
A new method to detect loss of heterozygosity using cohort heterozygosity comparisons Source: BMC Cancer - Tuesday, May 11, 2010
Commentary: Chronic Lymphocytic Leukemia--The Price of Progress. Source: The Oncologist - Tuesday, May 11, 2010
Review: Ofatumumab for the treatment of B-cell malignancies Source: NeLM - News - Monday, May 10, 2010
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Source: Haematologica - Monday, May 10, 2010
Rhodococcus equi Pneumonia in a Patient With Fludarabine-Treated Chronic Lymphocytic Leukemia and CD4-Lymphopenia. Source: The American Journal of the Medical Sciences - Monday, May 10, 2010
Expression of bone morphogenetic proteins (BMPs) receptors in patients with B-cell chronic lymphocytic leukemia (B-CLL) Source: Clinical and Laboratory Haematology - Sunday, May 09, 2010
Expression of bone morphogenetic proteins (BMPs) receptors in patients with B-cell chronic lymphocytic leukemia (B-CLL). Source: International Journal of Laboratory Hematology - Sunday, May 09, 2010
The Content of Elements in Rainwater and Its Relation to the Frequency of Hospitalization for Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia in Opole Voivodship, Poland, During 2000-2002. Source: Biological Trace Element Research - Saturday, May 08, 2010
Periorbital non-Hodgkin's lymphoma after blunt trauma Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Saturday, May 08, 2010
B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: a case–control study in Greece Source: Cancer Causes and Control - Saturday, May 08, 2010
Ligand substitution reactions and cytotoxic properties of [Au(L)Cl(2)](+) and [AuCl(2)(DMSO)(2)](+) complexes (L=ethylenediamine and S-methyl-l-cysteine). Source: Journal of Inorganic Biochemistry - Friday, May 07, 2010
Utility of Flow Cytometry as a Screening Tool for Transplant Donors for Chronic Lymphocytic Leukemia. Source: Acta Haematologica - Thursday, May 06, 2010
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia Source: Blood - Thursday, May 06, 2010
Chic adaptor regulates apoptosis in CLL Source: Blood - Thursday, May 06, 2010
Clinical Trials Target Lymphoma, Leukemia Source: Health News from Medical News Today - Thursday, May 06, 2010
High Concentrations of Anaerobic Adenosine-Triphosphate May Impair Apoptosis in Malignant B Cells From Patients With Chronic Lymphocytic Leukemia Source: Medscape Today Headlines - Thursday, May 06, 2010
Occupational exposure to solvents and risk of lymphoma subtypes: results from the Epilymph case-control study Source: Occupational and Environmental Medicine - Thursday, May 06, 2010
Epoetin Delta Reduces Oxidative Stress in Primary Human Renal Tubular Cells Source: Journal of Biomedicine and Biotechnology - Wednesday, May 05, 2010
Scott & White Healthcare clinical trials target lymphoma, leukemia Source: EurekAlert! - Medicine and Health - Wednesday, May 05, 2010
Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome Source: American Journal of Hematology - Tuesday, May 04, 2010